Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
—Funding to Enhance Research and Development of Pipeline, Including Lead Program Targeting Activated KRASG12C— —Proceeds to Further...